

STRATEGIC FOCUS ON QUALITY, PATIENT SAFETY AND RISK

1. Organisational quality priorities and outcomes to support quality and patient safety are agreed and reflected within an updated version of the Health Board's Quality Strategy/Plan.

| Action to be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status |
|---|-----------|------------------------|--|------------------------------------|--------|
| Review the quality section of the IMTP to integrate quality, PREMS, PROMS, quality improvement and audit outcomes through the plan (March 2020) | June 2020 | Director of Nursing | Complete | Quality and Safety Committee | |
| Further work is required to devise the quality priorities for the Health board using business intelligence approach from patient experience data – in particular serious incidents, Never Events and the learning and systematic change required (April 2020) | June 2020 | Director of Nursing | Being developed as part of 2019/20 AQS process | Quality and Safety Committee | |
| • Finalisation of the Quality and Safety Framework (January 2020) | June 2020 | Director of Nursing | New Quality and Safety Process Framework in place | Quality and Safety Committee | |
| Introduction of a Quality Improvement Hub (April 2020) | June 2020 | Director of Nursing | Part of Quality and Safety Governance Improvement plan 2020/21 | Quality and Safety Committee | |
| Undertake an analysis of Service Delivery Unit annual plans to monitor quality and safety priorities | June 2020 | Director of Nursing | Part of Health and Care Standards Self-Assessment 2019/20 process. Due to report | , , | |

| and objectives (April 2020) | | | to Board in May 2020 | | |
|--------------------------------------|-----------|-------------|--------------------------------|-------------|--|
| Develop specific targets for quality | | Director of | Being developed as part of | Quality and | |
| and safety which can be measured | | Nursing | 2019/20 AQS process | Safety | |
| for the Annual plan 2020-2021 | | | | Committee | |
| Develop KPI's for monitoring | June 2020 | Director of | Part of Health and Care | Quality and | |
| compliance against the Welsh | | Nursing | Standards Self-Assessment | | |
| Government's Health & Care | | | 2019/20 process. Due to report | Committee | |
| Standards framework (April 2020) | | | to Board in May 2020 | | |

2. The Board has a strategic and planned approach to improve risk management across the breadth of its services. This must ensure that all key strategies and frameworks are reviewed, updated and aligned to reflect the latest governance arrangements, specifically:

- *i.* The Board Assurance Framework (BAF) reflects the objectives set out in the current Integrated Medium Term Plan (IMTP)/annual plan and the organisation's quality priorities.
- *ii.* The Risk Management Strategy reflects the oversight arrangements for the BAF, the Quality and Patient Safety (Clinical) Governance Framework and any changes to the management of risk within the organisation.
- *iii.* The Quality and Patient Safety Governance Framework supports the priorities set out in the Quality Strategy/Plan and align to the Values and Behaviours Framework.

Terms of reference for the relevant Board committees, including those for Audit, Quality and Safety and Risk, and at divisional /group levels, reflect the latest governance arrangements cited within the relevant strategies and frameworks.

| - | Action to be taken | Timescale | Lead | Progress Report as 29 th | Committee | Status |
|------------|------------------------------------|------------|-------------|-------------------------------------|-----------|--------|
| | | | Executive | February 2020 | | |
| | • Finalise the Board Assurance | April 2020 | Director of | Board Assurance Framework | Audit | |
| | Framework (January 2020) | | Corporate | received by the Health Board in | Committee | |
| | | | Governance | January 2020 | | |
| | • Review the committee planners to | April 2020 | Director of | Committee Work Programmes | Audit | |
| 0392 | ensure risk reports are reported | - | Corporate | updated and risk reports now | Committee | |
| 25 | quarterly (January 2020) | | Governance | being considered by the | | |
| No. 51/25/ | | | | appropriate Committees | | |
| - | Review of terms of reference for | April 2020 | Director of | | Audit | |
| | Board Committees and Unit Boards | | Corporate | | Committee | |

| to ensure appropriate referencing to current policies (March 2020) | | Governance | | |
|---|---|--|--|--|
| To continue to review the risk management arrangements to focus on the appropriate level of risk currently being reported (quarterly) | - | Director of Corporate Governance | Risk Management arrangement continue to develop to ensure that risks are being managed appropriately. | |

LEADERSHIP, QUALITY AND PATIENT SAFETY

- **3.** There is collective responsibility for quality and patient safety across the executive team and clearly defined roles for professional leads:
 - *i.* The role of Executive Clinical Directors and divisional/group Clinical Directors in relation to quality and patient safety is clearly defined
 - *ii.* The roles, responsibilities, accountability and governance in relation to quality and patient safety within the divisions/groups/directorates is clear

There is sufficient capacity and support, at corporate and directorate level, dedicated to quality and patient safety.

| Action to be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status |
|--|-----------|--|--|------------------------------------|--------|
| The Clinical Directors will set out specifically the individual and collective responsibilities in relation to quality and safety (January 2020) | | Director of Nursing and Patient Experience, Medical Director and Director of Therapies and Health Science | Work is being progressed as part of change in line management responsibilities to ensure clarity on roles and responsibilities and an update will be brought to the Quality and Safety Committee March/April once finalised. | Quality and Safety Committee | |

| Ensure the roles and responsibilities are clearly set out in the quality and safety framework (January 2020) | Patient Experience, Medical Director and Director of Therapies and Health Science | To be updated once agreed. | Quality and Safety Committee |
|--|--|--------------------------------------|------------------------------------|
| ORGANISATIONAL SCRUTINY OF QUAI | | | |
| 4 The roles and function of the Quality and | d Safety Committee is fit for pu | irpose and reflects the Quality Stra | tegy Quality and Patient |

4. The roles and function of the Quality and Safety Committee is fit for purpose and reflects the Quality Strategy, Quality and Patient Safety Governance Framework and key corporate risks for quality and patient safety. This should include assessment of ensuring sub-groups/committees have sufficient support to function effectively; the content, analysis, clarity and transparency of information presented to the committee and the quality framework in place is used to improve oversight of quality and patient safety across the whole organisation.

| Action to be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status |
|---|------------|---|--|------------------------------------|--------|
| • The Quality & Safety Committee, will continue to improve the information it receives including the quality performance dashboard (March 2020) | April 2020 | Director of Nursing and Patient Experience and Director of Corporate Governance | QSGG reports monthly to QSC – revised reporting template reports business and matters for escalation mapped to the Health and Care standards | Quality and Safety Committee | |
| • Ensure that the Quality and Safety Governance Group meets regularly with clear and consistent reporting to the Quality & Safety Committee (January 2020). | April 2020 | Director of Nursing and Patient Experience and Director of Corporate Governance | QSGG reports monthly to QSC – revised reporting template reports business and matters for escalation mapped to the Health and Care standards | Quality and Safety Committee | |
| • Ensure that the new Head of | April 2020 | Director of | All SDU Q&S meetings are | Quality and | |

| Quality & Safety within corporate nursing team attends Unit Q&S meetings and main regular dialogue with Unit (representatives (April 2020). | s the ains | Nursing and Patient Experience and Director of Corporate Governance | attended by the Head or Deputy Head of Quality and Safety | Safety Committee | |
|--|-------------------------------|---|--|------------------------------------|--|
| , | afety April 2020 is hub | Director of Nursing and Patient Experience and Director of Corporate Governance | New Quality and Safety Process Framework in place | Quality and Safety Committee | |
| Pilot a quality KPI dashboard the aim of better triangulatio data across a range of sou (quantitative and qualita (March 2020) | n of rces | Director of Nursing and Patient Experience and Director of Corporate Governance | Part of Quality and Safety Governance Improvement plan 2020/21 | Quality and Safety Committee | |

233/125/1010 16:01 233/125/1010 16:01 16:010 16:01 16:010 16:01 10:06

5. Independent/Non-Executive Members are appropriately supported to meet their responsibilities through the provision of an adequate induction programme and ongoing development so they can effectively scrutinise the information presented to them.

| Action to be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status |
|--|------------|--|--|-----------------------------|--------|
| Continue to provide a tailored induction and IM development programme for members and ensure they attend the NHS Wales IM induction facilitated by Welsh Government and Academi Wales. | • | Director of Corporate Governance | Local induction in place which is complemented by the national induction. | Chairs Advisory Group | |
| To arrange specific training for Committee Chairs to ensure consistency across committees. | April 2020 | Director of Corporate Governance | Agreedtoarrangespecific/bespoketrainingtosupportallIMs.DiscussionunderwaywithAcademyWales. | Chairs Advisory Group | |
| Annual session on IM scrutiny as part on on-going development of Independent Members | April 2020 | Director of Corporate Governance | Included on the Board Development Programme | Health Board | |

6. There is sufficient focus and resources given to gathering, analysing, monitoring and learning from user/patient experience across the organisation. This must include use of real-time user/ patient feedback.

| Action to be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status |
|--|------------|---|--|-----------|--------|
| Develop a patient experience plan which sets out a range of activities undertaken by the Health Board to gain a picture of patient experiences, with the aim of identifying issues and good practice. To include detailed actions, timeframes and outcome measures. (April 2020) | April 2020 | Director of Nursing and Patient Experience | This will be encompassed into the development of a patient experience forum to be developed during 2020/21 financial year | | |
| • To review the current processes and system of managing concerns to ensure that the Board receives appropriate assurance | April 2020 | Director of Corporate Governance | The leadership for the team has just transferred to the Director of Corporate Governance. Work in progress to review and strengthen current processes. | Safety | |

ARRANGEMENTS FOR QUALITY AND PATIENT SAFETY AT DIRECTORATE LEVEL

7. There is visibility and oversight of clinical audit and improvement activities across divisions/groups/directorates and at corporate level. This includes identification of outliers and maximising opportunities for sharing good practice and learning.

| Action to b | be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status |
|---------------------|---|-----------|---------------------|---|------------------------------------|--------|
| review c to ensu | ecutive Medical Director will current reporting arrangements re appropriate oversight at a te and operational level. | June 2020 | Medical Director | Current arrangement for reporting through Directorate and Delivery Unit Quality and Safety structures will be strengthened by the establishment of a Clinical Outcomes and Effectiveness Group in April 2020 | Quality and Safety Committee | |
| reflect t | udit Policy will be developed to he four tiers of clinical audit ed above. | June 2020 | Medical Director | Communication issues to Delivery Units regarding expectation of audit plans to address areas of concern | Quality and Safety Committee | |
| | t in place a clear audit nme which provides coverage and national audits. | June 2020 | Medical Director | Audit programme reflects need for local, site-specific and cross- organisation audits as well as sharing lessons learned | Quality and Safety Committee | |

8. The organisation has clear lines of accountability and responsibility for quality and patient safety within divisions/groups/directorates.

| Action to be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status |
|---|------------|------------------------|--|------------------------------------|--------|
| Implement the Quality and Safety Framework (April 2020) | April 2020 | Director of Nursing | Quality and Safety Framework in place. | Quality and Safety Committee | |

IDENTIFICATION AND MANAGEMENT OF RISK

- **9.** The form and function of the divisional/group/directorate quality and safety and governance groups and Board committees have:
 - *i.* Clear remits, appropriate membership and are held at appropriate frequently.
 - *ii.* Sufficient focus, analysis and scrutiny of information in relation to quality and patient safety issues and actions.
 - iii. Clarity of the role and decision making powers of the committees

| | Action to be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status |
|--------|--|------------|------------------------|--|------------------------------------|--------|
| 1 | Finalise the Quality & Safety Framework, ensuring is it is supported by a quality hub (April 2020) | April 2020 | Director of Nursing | Quality and Safety Framework in place. | Quality and Safety Committee | |
| 03/25/ | Finalise the terms of reference for the Quality Governance Group (January 2020) Agree the reporting structure and | April 2020 | Director of Nursing | Terms of Reference reviewed and finalised. | Quality and Safety Committee | |
| | Agree the reporting structure and | April 2020 | Director of | Part of Quality and Safety | Quality and | |

| sub groups including the terms of | | Nursing | Governance Improvement plan | | |
|--|------------|------------------------|--|-----------|--|
| reference (March 2020) | | | 2020/21 | Committee | |
| As part of the operating model, issue a set of standards, including terms of reference, standard agendas to all Units (April 2020) | April 2020 | Director of Nursing | Part of Quality and Safety Governance Improvement plan 2020/21 | | |



MANAGEMENT OF INCIDENTS, CONCERNS AND COMPLAINTS

10. The organisation has clear and comprehensive risk management systems at divisional/group/directorate and corporate level, including the review and population of risk registers. This should include clarity around the escalation of risks and responsibilities at directorate and corporate level for risk registers and the management of those risks. This must be reflected in the risk strategy.

| Action to be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status |
|---|------------|--|--|--------------------|--------|
| Continue to embed and mature the risk management system across the organisation. Monitored quarterly by the Audit Committee | April 2020 | Director of Corporate Governance | Risk Management continues to be embedded. Regular reports to the Audit Committee. | Audit Committee | |
| As part of the Board Assurance Framework ensure sightedness of risks at an operational and corporate level. Board Assurance Framework to be reported to the Board in January (January 2020) | | Director of Corporate Governance | Board Assurance Framework considered by the Board. Further work to be undertaken on operational risks as part of the implementation in 2020. | Audit Committee | |

11. The oversight and governance of DATIX and other risk management systems ensures they are used as an effective management and learning tool. This should also include triangulation of information in relation to concerns, at a divisional/group/ directorate or corporate level, and formal mechanisms to identify and share learning.

| | Action to be taken | Timescale | Lead | Progress Report as 29 th | Committee | Status |
|-------|--|------------|-------------|-------------------------------------|-----------|--------|
| | | | Executive | February 2020 | | |
| | • The Risk Management group will | April 2020 | Director of | The Risk Management Group | Audit | |
| 1g | | - | Corporate | meets quarterly. Further work to | Committee | |
| 0,0,0 | oversight and governance of DATIX and risk management processes | | Governance | do in relation to the risk scrutiny | | |
| 12 | and risk management processes | | | and escalation. | | |
| | which ensures they are used as an | | | | | |
| | effective management and learning | | | | | |
| | · ° 6 | | | • | | |

| | ol. (Quarterly) | | | | | |
|---|--|-----------|---|---|---|-------|
| en ris | ne BAF will be developed further to nsure it fully aligns with the updated of management policy. (January 120) | | Director of Corporate Governance | Risk Management Policy approved by the Board. Continue development of the BAF. | Audit Committee | |
| The be up IN gr | he BAF is a living document and will be updated continuously (ongoing bodates against the HBRR, ITP/annual plan, clinical plan etc.) and conitored by the Risk Management oup with regular updates to the Audit committee and the Board. (Quarterly) | | Director of Corporate Governance | Agreed to be reported twice yearly to the Board and as part of the regular review of risk management arrangements. | Audit Committee | |
| | ANISATIONAL CULTURE AND LEA | | | | | |
| | cidents). In addition, staff are empowe | | | | | |
| | n to be taken | Timescale | Lead | Progress Report as 29 th | Committee | Statu |
| | , , , , , , , , , , , , , , , , , , , | | Lead Executive Director of Corporate Governance | Progress Report as 29 th February 2020 Complete. | Committee Quality and Safety Committee | Statu |

13. The organisation has an agreed Values and Behaviours Framework that is regularly reviewed, has been developed with staff and has a clear engagement programme for its implementation.

| Action to be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status |
|---|-----------|------------------------------------|---|----------------------------------|--------|
| All ongoing actions are being picked up as part of the Workforce and OD Framework | June 2020 | Director of Workforce and OD | W&ODC regularly review progress against the W&ODF as part of the routine assurance review of the Committee. All required actions being delivered in line with Framework requirements. | Workforce and OD Committee | |
| Re commission Guardian Service to continue post May 2020 | June 2020 | Director of Workforce and OD | Tender process in train. Further discussion with Tus panned to discuss ongoing commission | Workforce and OD Committee | |
| Continue with a series of further ACAS led 'Bullying' Workshops to run through 20/21 | June 2020 | Director of Workforce and OD | Further sessions commissioned and planned | Workforce and OD Committee | |
| Participate in the 'Just Culture' initiative as part of the 2 pathfinder organisations for NHS Wales. Participate in the two training events scheduled for March and May 2020 | June 2020 | Director of Workforce and OD | Health Board received an introduction to Just Culture at the latest Leadership Summit. Four day programme will be running in March. | Workforce and OD Committee | |
| Leadership Summit scheduled for February 2020 to focus on Compassionate Leadership (supported by Michael West) and Just Culture (support by Mersey Care) | June 2020 | Director of Workforce and OD | Completed. Update provided at Workforce and OD Committee | Workforce and OD Committee | |

| and across the NHS. | | | | | | | |
|---|-----------|--|---|------------------------------------|--------|--|--|
| Action to be taken | Timescale | Lead Executive | Progress Report as 29 th February 2020 | Committee | Status | | |
| • Review the reporting of Serious Incidents to the Quality and Safety Committee (March 2020) | | Director of Nursing | Complete – SI's are reported as individual item to QSC from QSGG with information flow agreed by Chair of QSC | Quality and Safety Committee | | | |
| Strengthen the reporting of inspections through the Quality and Safety Committee (April 2020) | June 2020 | Director of Corporate Governance | CHC Reports are now reported to the Committee. The reporting will be strengthened following the appointment of the Head of Compliance | Quality and Safety Committee | | | |
| • Ensure that outcomes of clinical audits, and inspections are reflected in the Board Assurance Framework (April 2020) | June 2020 | Director of Corporate Governance | Work in progress and to be included in the next update of the BAF. | Audit Committee | | | |
| Review the reporting and governance of clinical audits (Local and National) (April 2020) | June 2020 | Medical Director | Completed. Clinical Outcomes and Effectiveness Group being established, to report to Quality and Safety Assurance Group | Quality and Safety Committee | | | |